Navigation Links
International Committee Recommends Stringent Guidelines for Translating Stem Cell Therapies From the Lab Bench to the Bedside

PHILADELPHIA, June 12 /PRNewswire-USNewswire/ -- The Internet is rife with provider Web sites and patient testimonials touting exciting new stem cell treatments for paralysis, Parkinson's disease, heart failure and cancer. And every year, desperately ill patients travel thousands of miles to seek experimental stem cell therapies with bold claims of cures for such intractable diseases.

Few, if any, of these putative treatments are based on sound pre-clinical data that have been published in peer-reviewed journals. Today, there are no proven treatments based on stem cells other than those for blood disorders, like leukemia and immune deficiencies. All other stem cell treatments are still highly experimental.

At the sixth annual meeting of the International Society for Stem Cell Research, a task force of leaders in the field announced a draft set of guidelines to ensure that rigorous best practices are applied to the clinical translation of stem cell research from the laboratory to human subjects. The guidelines are the culmination of months of discussion by scientists, ethicists, public policymakers, clinicians, industry representatives and members of the public from 13 countries. (The full guidelines will be posted at

"These guidelines are critically important to the future success of the field," according to Dr. George Q. Daley, ISSCR president and associate director of the Stem Cell Program at Children's Hospital Boston. "Not only does the use of untested therapies put patients at risk, it jeopardizes the legitimate practice of all translational stem cell research."

In strongly worded language, the guidelines "condemn" the use of stem cell therapies outside of an established clinical trial, particularly when patients are charged for "advertised medical services that constitute experimental, unproven and unestablished interventions." The guidelines call upon regulators in countries where these putative therapies are offered to regulate such practices to prevent exploitation of vulnerable patients. The guidelines call upon scientists and clinicians to conduct research with transparency and adherence to rigorous independent scientific and ethical review.

The guidelines address three major areas of the clinical translational process involving all types of human stem cells and their direct derivatives, including cell processing and manufacturing; pre-clinical studies; and clinical research. The guidelines also make specific recommendations for ethical oversight, peer review of studies, informed consent and protection of subjects, avoidance of conflict of interest, clinical trial design and reporting, and long-term follow up of patients. Also addressed are issues of social justice, such as public engagement in policy making and fair access to treatment, in particular, offering affordable treatments to patients in resource-poor countries.

The guidelines do allow for treating a specific patient or small numbers of patients outside of a clinical trial in "exceptional circumstances of justified medical need" where reasonable scientific evidence exists that the patient or patients might benefit and not be harmed. All clinical trial regulations related to informed consent, clinical follow-up, independent expert review and institutional support and accountability still apply.

Following a solicitation of comment period from June 12 to Sept. 15, 2008, the task force will develop a final version of the guidelines, expected to be released by the end of the year. At that time, the ISSCR will release an advisory for patients considering stem cell therapy to help guide them in evaluating programs and treatments. The advisory will be posted on the ISSCR Web site,

The guideline's task force was chaired by Dr. Olle Lindvall and co-chaired by Dr. Insoo Hyun. Four working groups participated in their development: the Quality Control and Manufacturing Subcommittee, chaired by Dr. Mahendra Rao; the Preclinical Testing Subcommittee, chaired by Dr. Giulio Cossu; the Clinical Trials Subcommittee, chaired by Dr. Ira J. Fox; and the Social Justice Subcommittee, chaired by Dr. Laurie S. Zoloth.

The International Society for Stem Cell Research (ISSCR) is an independent, nonprofit membership organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell research and application.

To schedule an interview during the annual meeting or prior to the event, for call-in information, or for additional information, contact Meagan Comerford at (847) 509-1944 x246 or

A press conference on clinical translation will be held Thursday, June 12, 11:30 a.m. - 12:30 p.m. in Room 303 at the Pennsylvania Convention Center. Members of the press registered for the meeting are invited to attend. To join the conference by telephone, contact Patricia Sullivan at (847) 509-1944 or for access information.

Press Conference Room/Office Room 303. Speakerphone available. ISSCR staff is available to help schedule interviews. Wireless internet access available.

Press Interview Room. Room 302. To reserve the space to conduct interviews, sign up on the sheet posted outside the room.

Visit for more meeting details.

Contact: Meagan Comerford

+1 847 509-1944 ext. 246,

SOURCE International Society for Stem Cell Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Maternal malaria researcher wins prestigious international prize
2. DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France
3. 8th International Conference on Pain and Chemical Dependency
4. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
5. ATS Medical Products Prominently Featured in International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) Scientific Presentations
6. HealthSTAR Public Relations Joins GlobalCom PR-Network of International Agencies
7. The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
8. International Esthetics, Cosmetics & Spa Conference - Las Vegas
9. 6 Nobel Prize Winners at International Congress of Genetics
10. Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
11. International Diabetes Federation Commits to Improving Diabetes Education Globally Through Centres of Education
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... ... On November 10, 2015, Bohrer Brady, LLC filed a class and collective ... home health care worker who provided companionship services for the elderly, ill or disabled ... Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since January ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: AGN ... the New York State Attorney General,s ... Sherman Act, and other statutes with the Attorney General over ... to cease marketing and selling the now generic version of ... admits no liability, has released its counterclaims against ...
Breaking Medicine Technology: